AU4505199A - Methods and compositions for increasing penetration of hiv protease inhibitors - Google Patents

Methods and compositions for increasing penetration of hiv protease inhibitors

Info

Publication number
AU4505199A
AU4505199A AU45051/99A AU4505199A AU4505199A AU 4505199 A AU4505199 A AU 4505199A AU 45051/99 A AU45051/99 A AU 45051/99A AU 4505199 A AU4505199 A AU 4505199A AU 4505199 A AU4505199 A AU 4505199A
Authority
AU
Australia
Prior art keywords
compositions
methods
protease inhibitors
hiv protease
increasing penetration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45051/99A
Inventor
Kenneth Russell Brouwer
Joseph William Polli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU4505199A publication Critical patent/AU4505199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU45051/99A 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors Abandoned AU4505199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9812189 1998-06-05
GBGB9812189.0A GB9812189D0 (en) 1998-06-05 1998-06-05 Methods and compositions for increasing penetration of HIV protease inhibitors
PCT/EP1999/003827 WO1999064001A2 (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors

Publications (1)

Publication Number Publication Date
AU4505199A true AU4505199A (en) 1999-12-30

Family

ID=10833305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45051/99A Abandoned AU4505199A (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors

Country Status (5)

Country Link
EP (1) EP1094814A2 (en)
JP (1) JP2002517443A (en)
AU (1) AU4505199A (en)
GB (1) GB9812189D0 (en)
WO (1) WO1999064001A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
JP2000072749A (en) * 1998-08-24 2000-03-07 Mitsui Chemicals Inc Apoptosis-inducing agent using quinoline derivative
JP2000290181A (en) * 1999-04-01 2000-10-17 Mitsui Chemicals Inc Intracerebral migration potentiator for encephalopathy therapeutic agent
AU2002314914A1 (en) 2001-06-01 2002-12-16 Elan Pharmaceuticals, Inc. Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
MXPA03011521A (en) 2001-06-13 2004-03-18 Elan Pharm Inc Aminediols as agents for the treatment of alzheimer's disease.
MXPA04000337A (en) 2001-07-10 2004-07-23 Upjohn Co Aminediols for the treatment of alzheimer's disease.
MXPA04000338A (en) 2001-07-10 2004-07-23 Upjohn Co Diaminediols for the treatment of alzheimer's disease.
BR0213139A (en) 2001-10-04 2004-08-10 Elan Pharm Inc Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
BR0214736A (en) 2001-12-06 2004-11-23 Elan Pharm Inc Compound and its pharmaceutically acceptable salts, pharmaceutical composition and method of treating humans or animals suffering from diseases or conditions
AU2003303141A1 (en) 2002-04-30 2004-07-22 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
MXPA05011150A (en) 2003-04-21 2005-12-14 Elan Pharm Inc (HETERO) ARYLAMIDE 2-HYDROXY-3-DIAMINOALKANES FOR USE IN THE TREATMENT OF ALZHEIMERaCOES DISEASE.
JP2007528400A (en) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド Substituted hydroxyethylamine aspartic protease inhibitors
EP1740575A2 (en) 2004-04-22 2007-01-10 Eli Lilly And Company Pyrrolidine derivatives useful as bace inhibitors
EP1773756A2 (en) 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2014165087A1 (en) * 2013-03-12 2014-10-09 Hiv Diagnostics, Inc. Mdr method and products for treating hiv/aids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783680B2 (en) * 1991-01-11 1998-08-06 ラボラトワール、グラクソ、ソシエテ、アノニム Acridine derivative
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Also Published As

Publication number Publication date
JP2002517443A (en) 2002-06-18
GB9812189D0 (en) 1998-08-05
EP1094814A2 (en) 2001-05-02
WO1999064001A3 (en) 2000-02-03
WO1999064001A2 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
AU3972697A (en) Inhibitors of cysteine protease
AU4505199A (en) Methods and compositions for increasing penetration of hiv protease inhibitors
AU3665199A (en) Inhibitors of impdh enzyme
AU4429799A (en) Inhibitors of p38
AU3413100A (en) Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase
AU2001259100A1 (en) Joint compound and method of making same
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
AU1101501A (en) Methods and compositions for treatment of keratoconus using protease inhibitors
AU3118200A (en) Hiv integrase inhibitors
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
AU9059798A (en) Urokinase inhibitors
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
AU5463099A (en) Inhibitors of redox signaling and methods of using same
AU9624398A (en) Pyrrolopyrrolidine derivatives and their use as serine protease inhibitors
AU5205499A (en) Method for autoactivation of procaspase 8
AU2001233932A1 (en) Method and composition
AU2756301A (en) Compositions comprising genome segments and methods of using the same
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AU4980400A (en) Compositions and methods for detection of active proteases
AU5089699A (en) Methods of making dihydropyrone hiv protease inhibitors
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU2002239775A1 (en) Chemical-library composition and method
AU2221400A (en) Compositions containing and methods of using n-acyl-1h-aminoindenes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase